Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.
Smith & Nephew plc (NYSE: SNN, LSE: SN) is a global medical technology business whose news flow reflects activity across orthopaedics, sports medicine & ENT, and advanced wound management. Company announcements frequently highlight new product launches, clinical evidence, strategic partnerships and portfolio updates that are relevant to surgeons, healthcare providers and investors following SNN stock.
Recent news has showcased advanced wound management innovations, such as clinical data on the PICO◊ Single Use Negative Pressure Wound Therapy System demonstrating reductions in wound dehiscence, length of stay and costs versus an alternative device in orthopaedic and cardiovascular surgery, and studies on the ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing describing its mechanism in absorbing and dissipating shear forces linked to pressure injury risk.
In Sports Medicine, Smith+Nephew news items have covered the REGENETEN◊ Bioinductive Implant, including randomized controlled trial results and expanded indications to extra-articular ligament injuries, as well as updates on the CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant, including the establishment of a Category I CPT code recognising its clinical significance and adoption. Announcements also describe launches such as the Q-FIX™ KNOTLESS All-Suture Anchor and the CENTRIO Platelet-Rich-Plasma System for chronic exuding wounds.
Orthopaedics-related releases include the launch of the TRIGEN™ MAX Tibia Nailing System for tibial fractures and the expansion of CORIOGRAPH™ Pre-Op Planning and Modeling Services to total shoulder arthroplasty, alongside references to the AETOS◊ Shoulder System. Strategic and investor-focused news covers topics such as the RISE strategy, medium-term financial targets, and acquisitions like Integrity Orthopaedics and its Tendon Seam™ rotator cuff repair technology.
Visitors to this SNN news page can review these updates in one place, tracking how Smith & Nephew presents clinical data, regulatory milestones, portfolio expansions, partnerships with organisations such as UFC and Wimbledon, and capital markets communications that shape the company’s profile in the global medical technology sector.
Smith+Nephew (NYSE:SNN) has launched the CORI™ handheld robotics, an advanced solution for total and partial knee arthroplasties. This compact and mobile system integrates a 3-D imaging system with a robotic sculpting tool, allowing for personalized surgeries tailored to patient anatomy. Surgeons report improved patient outcomes, including less pain and greater satisfaction, as it enables tailored operations. The system aims to streamline surgical processes and is part of Smith+Nephew's five-year innovation strategy to enhance surgical experiences through digital technology.
Smith+Nephew (NYSE: SNN) has announced the establishment of a new digital surgery and robotics innovation center in Munich, Germany. This center aims to unite healthcare professionals from Europe, the Middle East, and Africa with Smith+Nephew's R&D teams to advance digital surgery technologies, including the CORI™ robotic system. The facility will feature a dedicated medical education area for hands-on learning and is scheduled to open in late 2022. This development follows the company's recent robotics facility in Pittsburgh, enhancing its collaborative approach to medical education and product development.
Smith+Nephew has established its first dedicated Medical Education Centre in Singapore to enhance the training of healthcare professionals in the Asia Pacific region. Set to begin operations by mid-2022, the centre will focus on digital and robotic surgery, integrating Smith+Nephew's Real Intelligence ecosystem. It will offer advanced training technologies including augmented reality and hands-on digital operating rooms. This initiative aligns with the company's mission to improve patient outcomes and support healthcare professionals' continuous education.
Smith+Nephew (NYSE:SNN) has launched the LEGION CONCELOC Cementless Total Knee System, showcasing its first completed surgeries. Utilizing CONCELOC Advanced Porous Titanium, this 3D printed technology promotes biological bone ingrowth for better long-term fixation. The system aims to streamline surgical efficiency, addressing challenges faced with traditional cementless designs. Now available in North America, it will expand into Europe and Asia Pacific pending regulatory approvals. This innovation positions Smith+Nephew in a growing market segment.
Smith+Nephew (NYSE:SNN) released a systematic review showing that its IODOSORB 0.9% Cadexomer Iodine Range is over twice as effective in healing chronic wounds compared to standard care. The analysis included 13 studies focusing on conditions like venous leg ulcers, diabetic foot ulcers, and pressure ulcers. IODOSORB significantly reduces barriers to healing such as exudate and bacteria. The cost of chronic wounds is estimated at $3.9 billion in Canada, highlighting the importance of effective treatments like IODOSORB in improving patient outcomes and reducing healthcare costs.
Smith+Nephew (NYSE:SNN) announced on Sept. 1, 2021, the launch of two innovations in its total knee arthroplasty (TKA) offerings: the JOURNEY II Medial Dished (MD) and SYNC Performance Instruments. These developments aim to enhance knee function and patient recovery. The JOURNEY II MD focuses on achieving natural knee kinematics, improving patient satisfaction with over 250,000 implementations reported. SYNC Performance Instruments streamline surgical procedures, reducing the number of instruments needed and enhancing ergonomics for surgeons, targeting a commercial release fall 2021.
Smith+Nephew (NYSE:SNN) announced enhancements to its Real Intelligence digital ecosystem and CORI Surgical System at the AAOS 2021 Annual Meeting. The highlights include the upcoming RI.HIP NAVIGATION software, pending FDA clearance, enabling robotic-assisted hip surgeries. Studies show that computer-guided technology significantly reduces revision rates (1.06% vs. 3.88%) and increases patient satisfaction. Furthermore, RI.INSIGHTS allows benchmarking for surgeons. The CORI System, noted for its portability and reduced costs, aims to innovate the orthopaedic space.
Smith+Nephew (NYSE:SNN) has announced the launch of its expanded Extremities portfolio at the American Academy of Orthopaedic Surgeons 2021 Annual Meeting in San Diego. This portfolio results from acquiring Integra LifeSciences' Extremity Orthopaedics business and features solutions for upper and lower extremity arthritis and fracture management. Notably, two products, the CADENCE Total Ankle Flat Cut Talar Dome System and the ATLASplan Shoulder 3D Planning System, were highlighted, aiming to enhance surgical efficiency and accuracy. The CADENCE system is targeted at treating end-stage ankle arthritis, while the ATLASplan software aims to improve shoulder surgical precision.
Smith+Nephew (LSE:SN, NYSE:SNN) announced new findings for its OR3O Dual Mobility Hip System and OXINIUM DH Technology at the AAOS 2021 Annual Meeting. Data demonstrates a significant reduction in material loss and corrosion in OXINIUM DH liners compared to CoCrMo liners. In-vitro tests indicated a substantial difference in metal ion elution, addressing concerns over CoCrMo implants. This technology, launched in 2019, captures 12% of primary hip replacements and 30% of revisions in the U.S., positioning Smith+Nephew as a competitive leader in the market.
Smith+Nephew (NYSE:SNN) has launched the WEREWOLF FASTSEAL 6.0 Hemostasis Wand, enhancing its radio-frequency technology for orthopaedic reconstruction. This innovation aims to aid surgeons by reducing blood loss and procedure time during total joint arthroplasty. The device's integration into the existing WEREWOLF platform allows for versatile use across specialties. Surgeon Ronald W. Singer praised its efficiency and ease of use. The launch underscores Smith+Nephew's commitment to advancing medical technology while improving patient outcomes.